Biotechnology company Calidi Biotherapeutics has been granted a US patent for its SuperNova (SNV) technology platform.
Calidi’s SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent. The company aims to use it in combination with various immunotherapy agents, including blocking antibodies. The SNV platform is designed to shield oncolytic viral payloads from the immune system, potentially delivering immuno-oncology therapies directly to tumour sites.
The company designed the platform to provide and improve therapeutic treatments for multiple cancer indications.
Calidi hopes its approach will induce a durable anti-tumour immune response. In pre-clinical studies, the platform was shown to shield the oncolytic viruses from destruction by the patient’s immune system, supporting efficient viral replication within the stem cells prior to delivery to tumor sites. Once there, the viral payload selectively destroys tumour cells and stimulates the patient’s immune system to attack the tumour.
Calidi was granted a patent for a combination immunotherapy approach for treatment of cancer by the US Patent and Trademark Office (USPTO).
Official comments
“Calidi’s Supernova platform has been developed through years of research in stem cell delivery and potentiation of oncolytic viruses and has the potential to revolutionise the treatment of solid tumours,” said Allan J. Camaisa, CEO and Chairman of Calidi. “The addition of this patent further strengthens our intellectual property position and solidifies the opportunity to use our platform technology in advancing therapeutic discovery and development through the FDA approval process.”
“Our outstanding team of doctors and scientists have invested years of intensive research and groundbreaking work to develop Calidi’s SNV platform technology,” said Boris Minev, President, Medical and Scientific Affairs at Calidi, and a patent inventor. “This patent represents the culmination of their impressive expertise, dedication, and passion, and will help the company continue to advance its novel discovery programmes.”
